MedTrace Logo

Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

NCT03080974 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-10-29

No results posted yet for this study

Summary

Compare the efficacy and tolerability of irreversible electroporation in combination with Nivolumab in patients with locally advanced pancreatic cancer.

Conditions

  • Pancreatic Adenocarcinoma

Interventions

DRUG

Nivolumab

Given post-operatively every two weeks for a total of 4 doses. Dose based on weight.

PROCEDURE

Irreversible Electroporation

Non-thermal ablation of tumor

Sponsors & Collaborators

  • University of Louisville

    lead OTHER

Principal Investigators

  • Robert Martin, MD, PhD · University of Louisville

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-14
Primary Completion
2028-06-01
Completion
2029-04-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03080974 on ClinicalTrials.gov